These data collectively suggested that AAV-mediated delivery of HMGB1 could ameliorate both of the nuclear and mitochondrial pathologies in SCA1 and thereby could rescue the clinical symptom and lifespan. This evidence concerns the gene HMGB1 and spinocerebellar ataxia type 1.